If you or a loved one has been diagnosed with ovarian cancer, navigating treatment options can feel overwhelming. From understanding what all the terms and wording mean to learning how clinical research studies, having a clear understanding of the information presented is key to making informed decisions and advocating for your care.
Eli Lilly and Company is conducting a two-part clinical research study testing a potential new medicine for people with platinum-sensitive and platinum-resistant ovarian cancer. Click here to learn more and review eligibility criteria.
Table of Contents
What Platinum-Resistant and Platinum-Sensitive Mean
Platinum-based chemotherapy has been a cornerstone of ovarian cancer treatment for decades. How your cancer responds to this therapy can help guide your next steps:
- Platinum-sensitive ovarian cancer (PSOC)
- Cancer responds to platinum-based treatments and does not return quickly after therapy
- Cancer may still be effectively managed with standard treatments
- Additional therapies could help maintain or extend remission
- Platinum-resistant ovarian cancer (PROC)
- Cancer either does not respond well to platinum-based therapy or returns within a short period after treatment
- Treatment decisions may be more complex
- Often requires exploring new approaches or combinations of therapies
Understanding these categories can help you have more meaningful conversations with your healthcare team about what treatments may be most appropriate.
Clinical Research Studies: An Option Alongside Standard Care
Clinical research studies are carefully designed studies that test new treatments or approaches to care. Participating in a clinical research study does not mean giving up standard treatment. In many cases, clinical research studies are offered alongside existing therapies, giving patients access to innovative options in addition to their current treatment.
Being eligible for a clinical research study depends on factors such as your disease type, prior treatments, and overall health. Eligibility criteria ensure that the clinical research study is appropriate for each participant and that safety is prioritized.
Research studies often focus on different aspects of ovarian cancer treatment, including:
- New or existing medications or combinations for PROC or PSOC
- Targeted therapies aimed at specific tumor characteristics
- Strategies to manage side effects and improve quality of life
Why Representation Matters
Historically, Black women and other underrepresented groups have joined clinical research studies at lower rates. This matters because diverse participation ensures that research reflects the populations most affected by ovarian cancer. Data from inclusive research studies can help doctors better understand how treatments work across different communities and improve care for everyone.
Joining a clinical research study is a way to contribute to how researchers understand ovarian cancer treatments.
Understanding Safety and Patient Rights
Clinical research studies have strict safety standards and oversight. Every study must follow regulations designed to protect participants, including:
- Monitoring by medical experts and independent committees
- Detailed protocols that guide safe dosing, monitoring, and follow-up
- Clear communication about potential risks and benefits
Participants are also fully informed about their rights before joining a clinical research study. You can ask questions, withdraw at any time, and make decisions alongside your healthcare team. In fact, asking questions is one of the most important ways to advocate for yourself and ensure you feel comfortable with your care plan.
Empowering Yourself Through Knowledge
Being informed about your disease, treatment options, and research opportunities allows you to participate actively in your care. Understanding whether your ovarian cancer is platinum-resistant or platinum-sensitive helps guide conversations with your doctor, while learning about clinical research studies simplifies the process and empowers you to consider all available options.
Clinical research studies don’t have to be a last resort. They are a practical way to access investigational therapies and contribute to research that benefits the broader community. For Black women and other underrepresented groups, participation is especially meaningful, helping ensure that research and future treatments are applicable to those who experience poorer outcomes.
If you are interested in learning more about ovarian cancer clinical trials and whether you may be eligible, Lilly’s clinical trial guide and pre-screener can help you explore options. Click here to learn more.
